



10-11-01

p 5

Please type a plus sign inside this box



PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/700,158
	Filing Date	November 10, 2000
	First Named Inventor	Rachel L. Allen et al.
	Group Art Unit	N/A
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Attorney Docket Number	HO-P02077US0

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	IDS Citation - PTO Form 1449 - (Listing References)
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	References (25)
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	Return Postcard
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual Name	FULBRIGHT & JAWORSKI L.L.P. Melissa W. Acosta
Signature	
Date	October 10, 2001

Transmittal	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EK102657424US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.	
Dated: October 10, 2001	Signature: <u>Staci Harris</u> (Staci Harris)

TECH CENTER 1600/2900

JUN 27 2002

RECEIVED

533 Rec'd PCT/PTO 10 OCT 21


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EK102657424US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: October 10, 2001

Signature:

(Staci Harris)

Docket No.: HO-P02077US0
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Rachel L. Allen, et al.

Application No.: 09/700,158

Group Art Unit: N/A

Filed: November 10, 2000

Examiner: Not Yet Assigned

For: NOVEL MOLECULE AND DIAGNOSTIC
METHOD

RECEIVED

JUN 27 20

TECH CENTER 1600/2000

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned. A copy of each reference on PTO/SB/08 is attached.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. 10025595.

Dated: October 10, 2001

Respectfully submitted,

By 

Melissa W. Acosta

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5407

(713) 651-5246



Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/700,158
				Filing Date	November 10, 2000
				First Named Inventor	Rachel L. Allen
				Group Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	HO-P02077US0

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A	PCT	WO 97/00084		Wiley, Don. C et al.	01-03-1997		
	B	PCT	WO 98/12221		Wildner, Gerhild	03-26-1998		
	C	PCT	WO 92/07070		Hammer, Robert E.	04-30/1992		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

RECEIVED
JUN 27 2002
TECH CENTER 1600/2900



Please type a plus sign (+) inside this box



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/700,158		
		Filing Date	November 10, 2000		
		First Named Inventor	Rachel L. Allen		
		Group Art Unit	N/A		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	HO-P02077US0

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	D	RAGHAVAN, MALINI et al. Extended repertoire of permissible peptide ligands for HLA-B*2702; Protein Science (1996); 5: 2080-2088.	
	E	WHELAN, MICHAEL A. et al. Chemical reactivity of an HLA-B27 thiol group; Eur. J. Immunol. 1993 23:3278-3285.	
	F	ALLEN, R et al. Abstract 72 Fifteenth Annual General Meeting of the British Society for Rheumatology, April 1998.	
	G	ALLEN, R et al. Cutting Edge: HLA-B27 Can Form a Novel β_2 -Microglobulin-Free Heavy Chain Homodimer Structure; Journal of Immunology, 1999; 162:5045-5048.	
	H	CUVELIER, C.A. et al. Expression of T cell receptors $\alpha\beta$ and $\gamma\delta$ in the ileal mucosa of patients with Crohn's disease and with spondylarthropathy; Clin exp Immunol. (1992) 90, 275-279	
	I	CRESSWELL, P and J. Dawson; Dimeric and Monomeric Forms of HL-A Antigens Solubilized by Detergent; Journal of Immunology, 1975 Vol 114, No. 1 Part 2.	
	J	CAPPS, G. George et al. In Vivo Dimeric Association of Class I MHC Heavy Chains: Possible Relationship to Class I MHC Heavy Chain- β_2 -Microglobulin Dissociation; Journal of Immunology; Vol. 151; 159-169, No. 1, 1993.	
	K	WEISS, GREGORY A. et al. Covalent HLA-B27/peptide complex induced by specific recognition of an aziridine mimic of arginine; Proc. Natl. Acad. Sci. USA Vol. 93, 10945-10948, 1996.	
	L	MCLEAN, L. et al. Cytokine profiles and site-directed B27 mutation in the HLA-B-27 transgenic rat; Genetic diversity of HLA; p 656-657.	
	M	MCLEAN, L. et al. Genetic diversity of HLA, Functional and Medical Implications, Paris EDK, Vol II, 656-7 and abstract 0396.	
	N	KHARE, S.D. et al. Spontaneous Inflammatory Arthritis in HLA-B27 Transgenic Mice Lacking β_2 -Microglobulin: A Model of Human Spondyloarthropathies; J. Exp. Med. 1995; 182; 1153-58	
	O	EZQUERRA, A. et al. Primary Structure of Papain-Solubilized Human Histocompatibility Antigen HLA-B27; Biochemistry 1985, 24, 1733-1741.	
	P	KHARE, S.D. et al. Spontaneous Inflammatory Disease in HLA-B27 Transgenic Mice is Independent of MHC Class II Molecules: A Direct Role for B27 Heavy Chains and Not B27-Derived Peptides; Journal of Immunology 1998, 160:101-106.	
	Q	KHARE, S.D. et al. HLA-B27 Heavy Chains Contribute to Spontaneous Inflammatory Disease in B27/human β_2 -Microglobulin (β_2 -m) Double Transgenic Mice with Disrupted Mouse β_2 -m. J. Clin. Invest. 1996, 98: 2746-2755.	
	R	JARDETZKY, T.S. et al. Identification of self peptides bound to purified HLA-B27; Nature Vo. 353 1991 p. 326-329.	
	S	GECZY, A.F. et al. A factor(s) in Klebsiella culture filtrates specifically modifies an HLA-B27-associated cell-surface component; Nature, Vol. 283, 1980, 782-785.	
	T	MACLEAN, L. et al. Sulphydryl reactivity of the HLA-B27 epitope: accessibility of the free cysteine studied by flow cytometry; Annals of the Rheumatic Disease 1992; 51; 456-460.	
	U	BENJAMIN, R. AND P. PARHAM; Guilt by association: HLA-B27 and ankylosing spondylitis; Immunology Today, 11, No. 4, 1990; 137-143.	
	V	EL-ZAATARI, FOUAD A.K. In Vitro Mutagenesis of HLA-B-27: Amino Acid Substitutions at Position 67 Disrupt Anti-B27 Monoclonal Antibody Binding in Direct Relation to the Size of the Sustituted Side Chain; The Journal of Immunology 1990; 144: 1512-1517, No. 4.	
	W	TAUROG, JOEL D. In Vitro Mutagenesis of HLA-B27; Substitution of an Unpaired Cysteine Residue in the α_1 Domain Causes Loss of Antibody-defined Epitopes; J. Clin. Invest. 1988, 82: 987-992.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached

RECEIVED

TECH CENTER 1600/2900

JUN 27 2002